In the midst of trade negotiations between India and the United States, one sector stands out with unshakeable confidence: pharmaceuticals. India’s edge in cost-effective drug production has made it indispensable to the US market, and the emerging trade deal is expected to deepen this reliance even further.
Speaking exclusively, Zota Healthcare’s Chairman Ketan Jota revealed that India rivals the US in FDA-approved facilities, fueling exports of generics and critical therapies for chronic diseases. ‘This deal is a strategic win,’ Jota asserted, crediting PM Modi’s negotiations for securing tariff concessions—a rarity from Washington.
Key exports include medications tackling lifestyle epidemics like diabetes, high blood pressure, and thyroid issues, which see relentless demand across the Atlantic. The agreement not only safeguards these flows but expands opportunities for both nations.
Adding momentum, the EU trade pact slashes duties to zero on pharma exports, paving the way for increased volumes and cutting-edge tech inflows. This will drive down costs in India, making life-saving drugs more accessible to millions of local patients.
As these pacts take shape, India’s pharma sector is on track for exponential growth in exports and innovation. The ripple effects promise a healthier economy and bolstered healthcare for everyday citizens, cementing India’s role as a global pharma leader.